Jifeng Feng Selected Research

Breast Neoplasms (Breast Cancer)

12/2023	circNFIB decreases synthesis of arachidonic acid and inhibits breast tumor growth and metastasis.
5/2023	Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer.
5/2023	Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.
2/2023	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
2/2023	Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
1/2023	Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
1/2023	Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy.
1/2023	NBDHEX re-sensitizes adriamycin-resistant breast cancer by inhibiting glutathione S-transferase pi.
1/2022	Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study.
11/2021	Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jifeng Feng Research Topics

Disease

106	Neoplasms (Cancer) 05/2024 - 12/2006
78	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 06/2002
32	Breast Neoplasms (Breast Cancer) 12/2023 - 11/2002
26	Lung Neoplasms (Lung Cancer) 03/2024 - 04/2008
23	Disease Progression 04/2024 - 08/2011
18	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 01/2013
16	Carcinogenesis 03/2024 - 04/2008
15	Neoplasm Metastasis (Metastasis) 12/2023 - 10/2017
14	Esophageal Squamous Cell Carcinoma 04/2024 - 01/2019
14	Adenocarcinoma of Lung 11/2023 - 02/2015
13	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2024 - 04/2014
12	Stomach Neoplasms (Stomach Cancer) 06/2022 - 02/2002
11	Exanthema (Rash) 01/2022 - 08/2011
10	Neutropenia 05/2023 - 08/2011
7	Hypertension (High Blood Pressure) 02/2024 - 01/2021
7	Diarrhea 01/2022 - 01/2015
6	Thrombocytopenia (Thrombopenia) 03/2024 - 08/2011
5	Esophageal Neoplasms (Esophageal Cancer) 05/2024 - 01/2016
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2023 - 04/2016
5	Stomatitis 12/2023 - 02/2014
5	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 01/2009
5	Leukopenia 01/2022 - 02/2002
5	Carcinoma (Carcinomatosis) 01/2021 - 06/2017
5	Vomiting 01/2020 - 02/2002
5	Lymphatic Metastasis 10/2017 - 02/2002
4	Triple Negative Breast Neoplasms 01/2024 - 10/2014
4	Fatigue 12/2023 - 01/2009
4	Nausea 01/2020 - 02/2002
4	Acne Vulgaris 01/2018 - 02/2014
3	Adenocarcinoma 06/2022 - 01/2020
3	Cognitive Dysfunction 04/2022 - 01/2022
3	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 12/2019
3	Pain (Aches) 01/2022 - 01/2018
3	Nasopharyngeal Carcinoma 12/2021 - 01/2020
3	Hypoxia (Hypoxemia) 01/2021 - 01/2019
3	Brain Neoplasms (Brain Tumor) 01/2021 - 01/2017
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 12/2014

Drug/Important Bio-Agent (IBA)

25	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2014
22	Cisplatin (Platino)FDA LinkGeneric 05/2022 - 02/2002
20	PlatinumIBA 04/2024 - 12/2006
20	Long Noncoding RNAIBA 12/2021 - 12/2014
16	ErbB Receptors (EGF Receptor)IBA 02/2023 - 01/2013
16	Gefitinib (Iressa)FDA Link 01/2022 - 09/2013
13	Proteins (Proteins, Gene)FDA Link 02/2024 - 01/2013
12	Rituximab (Mabthera)FDA Link 01/2024 - 04/2014
12	MicroRNAs (MicroRNA)IBA 01/2023 - 10/2016
11	Docetaxel (Taxotere)FDA Link 04/2024 - 01/2019
11	Tyrosine Kinase InhibitorsIBA 12/2022 - 08/2011
10	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2020
10	AfatinibIBA 01/2022 - 02/2014
8	camrelizumabIBA 05/2024 - 12/2019
8	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 12/2006
8	RNA (Ribonucleic Acid)IBA 12/2023 - 01/2019
8	Trastuzumab (Herceptin)FDA Link 02/2023 - 11/2017
8	Paclitaxel (Taxol)FDA LinkGeneric 06/2022 - 07/2011
7	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 02/2002
7	icotinibIBA 01/2017 - 09/2013
6	Indicators and Reagents (Reagents)IBA 05/2024 - 01/2019
6	Alanine Transaminase (SGPT)IBA 02/2024 - 08/2011
6	B7-H1 AntigenIBA 08/2023 - 01/2019
6	Hormones (Hormone)IBA 05/2023 - 01/2019
5	Biosimilar PharmaceuticalsIBA 01/2024 - 01/2020
5	anlotinibIBA 12/2023 - 01/2021
5	Capecitabine (Xeloda)FDA Link 01/2023 - 10/2019
5	Liver X ReceptorsIBA 02/2019 - 01/2017
5	Gemcitabine FDA Link 01/2018 - 07/2011
4	CrizotinibIBA 02/2024 - 08/2019
4	Circular RNAIBA 12/2023 - 10/2018
4	Glutathione Transferase (Glutathione S-Transferase)IBA 01/2023 - 10/2007
4	Fulvestrant (Faslodex)FDA Link 01/2023 - 01/2011
4	EnzymesIBA 01/2023 - 02/2010
4	LigandsIBA 12/2022 - 01/2018
4	Cetuximab (Erbitux)FDA Link 05/2022 - 08/2015
4	NivolumabIBA 03/2022 - 01/2019
4	Pemetrexed (MTA)FDA Link 01/2022 - 02/2014
4	Bevacizumab (Avastin)FDA Link 01/2022 - 07/2015
4	Taxoids (Taxanes)IBA 01/2021 - 10/2016
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 08/2011
4	Therapeutic UsesIBA 01/2018 - 11/2015
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2024 - 01/2016
3	Anaplastic Lymphoma KinaseIBA 02/2024 - 12/2016
3	ensartinibIBA 02/2024 - 01/2020
3	Cell-Free Nucleic AcidsIBA 01/2024 - 01/2017
3	C-Reactive ProteinIBA 01/2024 - 01/2022
3	AlbuminsIBA 01/2024 - 03/2022
3	Etoposide (VP 16)FDA LinkGeneric 12/2023 - 02/2002
3	exemestane (Aromasin)FDA Link 05/2023 - 01/2019
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 02/2002
3	human ERBB2 proteinIBA 01/2023 - 10/2019
3	Lapatinib (GW572016)FDA Link 01/2023 - 10/2019
3	apatinibIBA 06/2022 - 10/2014
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 06/2022 - 10/2007
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 01/2020
3	pyrotinibIBA 01/2021 - 10/2019
3	Monoclonal AntibodiesIBA 01/2021 - 01/2013
3	Messenger RNA (mRNA)IBA 05/2019 - 10/2018

Therapy/Procedure

73	Drug Therapy (Chemotherapy) 04/2024 - 02/2002
59	Therapeutics 04/2024 - 11/2002
16	Immunotherapy 05/2024 - 01/2018
9	Radiotherapy 01/2024 - 12/2002